Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2011

01-04-2011 | Research Article

Dose standardisation of anticancer drugs

Authors: Anne-Lise Pouliquen, Laurence Escalup, Nathalie Jourdan, Paul Cottu, Pierre Faure, Isabelle Madelaine-Chambrin

Published in: International Journal of Clinical Pharmacy | Issue 2/2011

Login to get access

Abstract

Objective of the study Body size based dosing is often used for prescribing anticancer drugs. However the scientific and the clinical rationales of this historical method have recently been criticized. As a result, alternative dosing strategies have been suggested, as flat-fixed dosing regimens, but not implemented in routine practice. Dose standardisation is a first step in order to rationalise chemotherapy dose calculation. A new method, derived from dose-banding, was developed, taking into account prescription and economic criteria. Setting Feasibility and interest of this concept were studied in two French cancer centres Institut Curie and Hôpital Saint-Louis. Main outcome measures The aim of our study was to assess dose standardisation of expensive anticancer drugs in objectives of quality and economy. Method Nine candidate drugs were selected and standardized rounded doses (SRD) were proposed. To determine the specific standard doses of these two centres, two theoretical and practical methods were applied, and then, their results were compared. For each anticancer drug the objective was to fix SRD in order to cover all the doses most frequently prescribed. Results It has been possible to propose SRD for six of the nine drugs. These SRD have been implemented with the agreement of the medical staff. These doses are, whenever possible, rounded to the nearest vial size, or correspond to a combination of the different strength of the commercial drug. Conclusion Our study shows that dose standardisation is a help to optimise the productivity and improve the organisation of the preparation unit.
Literature
1.
go back to reference DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71. DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
2.
go back to reference Pinkel D. Cancer chemotherapy and body surface area. J Clin Oncol. 1998;16:3714–5.PubMed Pinkel D. Cancer chemotherapy and body surface area. J Clin Oncol. 1998;16:3714–5.PubMed
3.
go back to reference Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44.PubMed Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44.PubMed
4.
go back to reference Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics. 1950;5:783–90.PubMed Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics. 1950;5:783–90.PubMed
6.
go back to reference Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590–611.PubMed Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590–611.PubMed
7.
go back to reference Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol. 1993;32:411–8.PubMedCrossRef Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol. 1993;32:411–8.PubMedCrossRef
8.
go back to reference Newell DR. Getting the right dose in cancer chemotherapy–time to stop using surface area ? Br J Cancer. 2002;86:1207–8.PubMedCrossRef Newell DR. Getting the right dose in cancer chemotherapy–time to stop using surface area ? Br J Cancer. 2002;86:1207–8.PubMedCrossRef
9.
go back to reference Markman M. ‘Flat-fixed dosing’ of chemotherapy: a concept whose time has come? Curr Oncol Rep. 2005;7:1–2.PubMedCrossRef Markman M. ‘Flat-fixed dosing’ of chemotherapy: a concept whose time has come? Curr Oncol Rep. 2005;7:1–2.PubMedCrossRef
10.
go back to reference Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82:323–5.PubMedCrossRef Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82:323–5.PubMedCrossRef
11.
go back to reference Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677–84.PubMedCrossRef Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677–84.PubMedCrossRef
13.
go back to reference Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001;58:1760–4.PubMed Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm. 2001;58:1760–4.PubMed
14.
go back to reference Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol. 2006;24:1499–506.PubMedCrossRef Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol. 2006;24:1499–506.PubMedCrossRef
15.
go back to reference Vigneron J. Stability studies of drugs used in oncology: the role of the hospital pharmacist. Eur J Hosp Pharm Pract. 2006;12:75–6. Vigneron J. Stability studies of drugs used in oncology: the role of the hospital pharmacist. Eur J Hosp Pharm Pract. 2006;12:75–6.
16.
go back to reference de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract. 2007;13:27–31.PubMedCrossRef de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract. 2007;13:27–31.PubMedCrossRef
17.
go back to reference Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171–7.PubMedCrossRef Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19:171–7.PubMedCrossRef
18.
go back to reference Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst. 2002;94:1883–8.PubMed Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst. 2002;94:1883–8.PubMed
19.
go back to reference Leveque D. Use of body weight and body surface area in dosing of anticancer agents in adult patients. Bull Cancer. 2007;94:647–51.PubMed Leveque D. Use of body weight and body surface area in dosing of anticancer agents in adult patients. Bull Cancer. 2007;94:647–51.PubMed
20.
go back to reference Kaestner SA, Sewell GJ. Chemotherapy dosing part II: alternative approaches and future prospects. Clin Oncol (R Coll Radiol). 2007;19:99–107. Kaestner SA, Sewell GJ. Chemotherapy dosing part II: alternative approaches and future prospects. Clin Oncol (R Coll Radiol). 2007;19:99–107.
21.
go back to reference Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice. 1998;4:10–4.CrossRef Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Practice. 1998;4:10–4.CrossRef
22.
go back to reference Leach RH, Whitmarsh S, Partridge C, Potter SR. New cytotoxics production unit at University hospital, Birmingham. Hosp Pharm. 2000;7:109–10. Leach RH, Whitmarsh S, Partridge C, Potter SR. New cytotoxics production unit at University hospital, Birmingham. Hosp Pharm. 2000;7:109–10.
23.
go back to reference MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J. 2003;270:691–3. MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J. 2003;270:691–3.
24.
go back to reference Leth-Miller D. Dose-banding of gemcitabine. Eur J Hosp Pharm Pract. 2007;2:52. Leth-Miller D. Dose-banding of gemcitabine. Eur J Hosp Pharm Pract. 2007;2:52.
25.
go back to reference Hirte HW, Kagoma S, Zhong L, et al. Dose banding of chemotherapy doses at the Juravinski Cancer Centre. J Clin Oncol. 2006;24:6099. (abstract). Hirte HW, Kagoma S, Zhong L, et al. Dose banding of chemotherapy doses at the Juravinski Cancer Centre. J Clin Oncol. 2006;24:6099. (abstract).
26.
go back to reference Kaestner S, Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract. 2007;13:109–17.PubMedCrossRef Kaestner S, Sewell G. Dose-banding of carboplatin: rationale and proposed banding scheme. J Oncol Pharm Pract. 2007;13:109–17.PubMedCrossRef
27.
go back to reference Kaestner S, Sewell GJ. A National Survey Investigating UK Prescribers’ Opinions on Chemotherapy Dosing and ‘Dose-Banding’. Clin Oncol (R Coll Radiol). 2009;21:320–8. Kaestner S, Sewell GJ. A National Survey Investigating UK Prescribers’ Opinions on Chemotherapy Dosing and ‘Dose-Banding’. Clin Oncol (R Coll Radiol). 2009;21:320–8.
28.
go back to reference Bonnabry P, Cingria L, Ackermann M, Sadeghipour F, Bigler L, Mach N. Use of prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care. 2005;18:9–16.PubMedCrossRef Bonnabry P, Cingria L, Ackermann M, Sadeghipour F, Bigler L, Mach N. Use of prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care. 2005;18:9–16.PubMedCrossRef
29.
go back to reference Chen CS, Seidel K, Armitage JO, et al. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997;3:331–40.PubMed Chen CS, Seidel K, Armitage JO, et al. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997;3:331–40.PubMed
30.
go back to reference Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef
31.
go back to reference Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hosp Pharm Eur. 2006;26:33–4. Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hosp Pharm Eur. 2006;26:33–4.
32.
go back to reference Kaestner S, Walker V, Roberts S, Perren T, Sewell G. Clinical and pharmacokinetic (pk) study on “dose-banded” and individual-dose chemotherapy: An interim report. J Oncol Pharm Practice. 2004;10:100. Kaestner S, Walker V, Roberts S, Perren T, Sewell G. Clinical and pharmacokinetic (pk) study on “dose-banded” and individual-dose chemotherapy: An interim report. J Oncol Pharm Practice. 2004;10:100.
33.
go back to reference Gillian A. British Oncology Pharmacy Association: www.bopawebsite.org. Toolkit: How to implement dose banding of chemotherapy. Accessed on 08/09/2008. Gillian A. British Oncology Pharmacy Association: www.​bopawebsite.​org. Toolkit: How to implement dose banding of chemotherapy. Accessed on 08/09/2008.
Metadata
Title
Dose standardisation of anticancer drugs
Authors
Anne-Lise Pouliquen
Laurence Escalup
Nathalie Jourdan
Paul Cottu
Pierre Faure
Isabelle Madelaine-Chambrin
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2011
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9478-6

Other articles of this Issue 2/2011

International Journal of Clinical Pharmacy 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine